Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

Completed 15 enrolled Massachusetts General Hospital National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.

Timeline

Start: 2009-02
Primary completion: 2010-04
Completion: 2010-04

Outcome

Met primary endpoint

paper Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004) PMID 20943777 ↗

Publications

Results Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. doi: 10.1210/jc.2010-1587. Epub 2010 Oct 13.
Makimura H, Stanley TL, Chen CY, Branch KL, Grinspoon SK. Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor. Growth Horm IGF Res. 2011 Jun;21(3):155-9. doi: 10.1016/j.ghir.2011.03.009. Epub 2011 Apr 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tesamorelin	Peptide	2 mg	Subcutaneous

Indications

No indication recorded.